Data temporarily unavailable
Unable to load analysis for « - » for now. Try again in a few moments.

Investlytic score: 0/5 criteria met.
- ❌ Price trend failed
- ⚠️ Mixed growth
- ❌ Debt failed
- ❌ P/E failed
- ❌ Correction failed
Price trend
Overall trend (8 years): insufficient progression (less than x1.5).
Price change 2018 → 2019: 84.59%
Price change 2019 → 2020: -14.76%
Price change 2020 → 2021: -26.96%
Price change 2021 → 2022: -28.00%
Price change 2022 → 2023: -84.28%
Price change 2023 → 2024: -61.04%
Price change 2024 → 2025: 418.25%
Price change 2025 → 2026: 7.04%
Price change 2026 (year to date): 12.32%
Financial growth
Revenue CAGR (8 years): 20.30%
Earnings CAGR (8 years): N/A
Growth status: positive trend (>1%/yr) in revenue, earnings data insufficient/N/A.
Debt
Debt-to-equity ratio: 1267145000.00
Debt/equity > 0.5 (maximum threshold).
P/E (Price/Earnings)
P/E ratio: -5.17
P/E > 25.0 (maximum threshold).
Correction (6 months)
Current correction: 33.82% from the high over 6 months.
Excessive correction (> 20.0%).
Criteria of the Investlytic model
- / 5Free with the Investlytic logo. Paste this line into your page: options.
<script src="https://investlytic.co/encart.js" data-symbole="IDIA.SW" data-lang="en"></script>Price trend
Price & trend
Interactive chart →💰 Dividend
Dividend ranking →⚖️ Comparison with the market
All stocks →| Stock | P/E | Dette/FP | Revenue growth | Rating |
|---|---|---|---|---|
| Idorsia Ltd | – | – | – | 🔒 |
| Clariane SE | 565.5 | 2.16 | +12.4 % | – |
| Emeis | – | 6.11 | +11.4 % | – |
| Lumibird S.A. | 37.3 | 0.71 | +9.8 % | – |
| Virbac S.A. | 19.4 | 0.26 | +6.5 % | ★ 4/5 |
Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.
Detailed analysis · Price trend
-
Revenues & profits
Revenue and net income
Financial indicators
Annual financial statements
| Fiscal year | Revenue | Net income | Net margin | EPS | Revenue growth |
|---|
Key reported figures
Revenue, net income and net margin reported by Idorsia Ltd over the latest fiscal years.
| Fiscal year | Revenue | Net income | Net margin | Revenue growth |
|---|---|---|---|---|
| 2020 | 85.6 m | -531 m | -620.3 % | n/a |
| 2021 | 42.2 m | -757 m | -1,795.2 % | -50.7 % |
| 2022 | 116 m | -988 m | -852.6 % | +174.7 % |
| 2023 | 182 m | -355 m | -195.5 % | +56.9 % |
| 2024 | 134 m | -315 m | -234.4 % | -26.2 % |
| 2025 | 264 m | -134 m | -50.7 % | +96.4 % |
Amounts converted to USD. Source: published annual accounts, collected on 13/11/2026.
Accounts and financial health
Balance sheet and cash flow published by Idorsia Ltd over the last fiscal years, strength scores and valuation by discounted cash flow (DCF).
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash and investments | 1.0 bn | 476 m | 158 m | 124 m | 87.2 m |
| Total Debt | 1.2 bn | 1.2 bn | 1.2 bn | 1.3 bn | 1.3 bn |
| Net Debt | 1.1 bn | 1.1 bn | 1.1 bn | 1.2 bn | 1.2 bn |
| Equity | 104 m | -661 m | -969 m | -1.2 bn | -1.1 bn |
| Total assets | 1.5 bn | 904 m | 500 m | 506 m | 466 m |
| Operating cash flow | -590 m | -859 m | -629 m | -370 m | -153 m |
| Investments (capex) | 30.9 m | 27.1 m | 9.1 m | 3.0 m | 471,000 |
| Free cash-flow | -621 m | -886 m | -639 m | -373 m | -167 m |
| Share buybacks | 418,000 | 0 | 197,000 | 0 | 0 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 |
Amounts in CHF, currency of the published accounts.
Trailing 12-month ratios
Altman Z: default risk estimated from the balance sheet and earnings. Piotroski: 9 tests on profitability, debt and efficiency. DCF: estimated value from discounted future cash flows, a model and not a forecast. Source: annual accounts published by the company, data as of 20/11/2026.
Valuation and competitors
Idorsia Ltd compared with its sector on the same exchange and with its main competitors.
Direct competitors
| Company | Market cap (USD) | P/E | Net margin |
|---|---|---|---|
| Idorsia Ltd | 1.3 bn | n/a | -50.7 % |
| Basilea Pharmaceutica AG BSLN.SW | 1.1 bn | 17.1 | 17.3 % |
| PolyPeptide Group AG PPGN.SW | 1.6 bn | 101.6 | -5.4 % |
| Kuros Biosciences AG KURN.SW | 923 m | 107.6 | 1.8 % |
| Molecular Partners AG MOLN.SW | 110 m | n/a | 0.0 % |
| Santhera Pharmaceuticals Holding AG SANN.SW | 267 m | n/a | -63.8 % |
| Medartis Holding AG MED.SW | 1.6 bn | 90.8 | 3.1 % |
| Addex Therapeutics Ltd ADXN.SW | 4.9 m | n/a | -3,889.6 % |
Trailing 12-month P/E. Sector: median of companies in the same sector listed on the same exchange, collected on 13/11/2026. Competitors: comparable companies named by the data provider.
Dividends and earnings
Idorsia Ltd: dividend history, last distributions, stock splits and earnings releases.
Latest ex-dividend dates
| Ex-dividend | Amount | Payment |
|---|---|---|
| 16/06/2017 | 11.84 CHF | n/a |
Earnings releases
| Date | Published EPS | Expected EPS | Surprise |
|---|---|---|---|
| 29/10/2026 | -0.17 | -0.19 | n/a |
| 30/07/2026 | -0.16 | -0.19 | n/a |
| 28/04/2026 | -0.14 | -0.18 | n/a |
| 26/02/2026 | -0.27 | -0.20 | n/a |
| 30/10/2025 | -0.40 | -0.22 | n/a |
| 30/07/2025 | -0.06 | -0.20 | n/a |
Stock splits
| Date | Operation |
|---|---|
| 13/10/2020 | split: 1,013 shares for 1,000 |
Factual data: ex-dividend history and earnings calendar, as of 20/11/2026. A past dividend does not guarantee the next one.
Who owns the stock
Free float, institutional investors, large funds, executives and elected officials: declared positions in Idorsia Ltd.
Sources: 13F filings (quarter shown), executives' Form 4 filings and US Congress members' disclosures, collected on 14/11/2026. Detailed disclosure obligations mainly apply to companies listed in the United States.
PEA and practical information
Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.
Frequently asked questions about Idorsia Ltd
What is the Idorsia Ltd share price?
Latest recorded price: 3.91 CHF on 13/11/2026, for a market cap of 1.3 bn USD.
What is the revenue of Idorsia Ltd?
264 m USD for fiscal year 2025, with net income of -134 m USD (net margin -50.7 %).
Does Idorsia Ltd pay a dividend?
Yes. Latest dividend: 11.84 CHF per share, ex-dividend on 16/06/2017. Over 12 months: 0.0000 CHF. Yield on the latest known price: 0.0 %.
Is Idorsia Ltd stock eligible for the French PEA?
No: the company is headquartered outside the European Union and the European Economic Area (ISIN CH0363463438).
How many employees does Idorsia Ltd have?
636 full-time employees according to the latest published profile.
Who runs Idorsia Ltd?
Andre C. Muller is the company's chief executive.